GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0174-0833 in Chinese Male Subjects Being Normal Weight, Overweight or With Obesity

Lead sponsor

Novo Nordisk A/S

Asset

CagriSema / cagrilintide

Subcutaneous · GLP-1 / amylin

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criteria

•BMI 20-39.9•Male

Primary endpoint

•AUC0-∞, NNC0174-0833

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05254158

Org study IDNN9838-4615

Secondary IDU1111-1247-7538World Health Organization (WHO)

Timeline

Milestones

Study first posted2022-02-24actual

Study start2022-03-03actual

Primary completion2022-09-07actual

Study completion2022-09-07actual

Last update posted2023-11-07actual

Assets

Investigational agents

CagriSema / cagrilintide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexMale

Healthy volunteersAccepted

Eligibility criteria

Key inclusion criteria

•Chinese male subject aged 18-55 years (both inclusive) at the time of signing informed consent.

•Body mass index (BMI) between 20.0 and 39.9 kg/m^2 (both inclusive) at screening.

•Body weight between 60.0 and 110.0 kg (both inclusive) at screening.

Key exclusion criteria

•Male subject who is not sexually abstinent or surgically sterilised (vasectomy) or who or whose partner(s) is not willing to use highly effective contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').

•Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Change in body weight

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

Body weight, % change

percent change from baseline, improvement

Safety / tolerability / PK

7 endpoints

Primary/protocol endpoint

AUC0-∞, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after a single dose

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

AUC0-168, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to 168 hours after a single dose

Time frame:From pre-dose (Day 1) to Visit 3 (Day 8)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Cmax, NNC0174-0833: The maximum concentration of NNC0174-0833 in plasma

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

Cmax

concentration, descriptive

Secondary/protocol endpoint

tmax, NNC0174-0833: The time from dose administration to maximum plasma concentration of NNC0174-0833

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

Tmax

descriptive

Secondary/protocol endpoint

t1/2, NNC0174-0833: The terminal half-life of NNC0174-0833

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

Half-life

descriptive

Secondary/protocol endpoint

CL/FNNC0174-0833: The apparent total plasma clearance of NNC0174-0833

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

descriptive

Secondary/protocol endpoint

Vz/FNNC0174-0833: The apparent volume of distribution of NNC0174-0833 in the terminal phase

Time frame:From pre-dose (Day 1) to Visit 7 (Day 36)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.